Episode Details
Back to Episodes
FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICU
Description
In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including:
- The role of novel β-lactam/β-lactamase inhibitor combinations
- Use of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogens
- Application of rapid diagnostic testing in critically ill patients with pneumonia, including current limitations
- Implementation of advanced antibiograms and clinical prediction scores
- Clinical utility of biomarkers for pneumonia (eg, procalcitonin)
- Application of updated nosocomial pneumonia classifications in clinical practice
Faculty:
Marion Elligsen, BScPhm, MSc, RPh, ACPR
Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Andrew Shorr, MD, MPH, MBA
Director
Pulmonary and Critical Care Medicine
Medstar Washington Hospital Center
Washington, DC
Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/3HaZpYw
Link to downloadable slideset:
https://bit.ly/3UxHoqr
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.